Literature DB >> 9990406

Resistance to antibiotics used in dermatological practice.

F Espersen1.   

Abstract

The increased prevalence of bacterial resistance is one of the major problems of medicine today. Antibiotic resistance can be defined as the situation where the minimal inhibitory concentration is greater than the concentration obtainable in vivo. Resistance genes are easily transferred among bacteria, especially bacteria on skin and mucous membranes. In dermatological patients the most important resistance problems are found among staphylococci, Propionibacterium acnes and, to some extent, streptococci. Staphylococcus aureus strains have developed worldwide resistance to penicillin due to betalactamase production in > 90% of cases, and methicillin resistance is now a major problem with resistance levels of > 50% in certain areas of the world. These resistant strains are often multiresistant, and include resistance to erythromycin and tetracycline, with resistance to quinolone developing rapidly. Group A streptococci are still susceptible to penicillin, but increasing problems with erythromycin and tetracycline have been reported. After treatment with both systemic and oral antibiotics, P. acnes develops resistance in more than 50% of cases, and it is estimated that one in four acne patients harbours strains resistant to tetracycline, erythromycin, and clindamycin. To limit the development of antibiotic resistance, it is necessary to establish an antibiotic policy (prescription rules, reimbursement strategy, development of both national and local guidelines, and limitations on non-medical use). Clinicians also need access to rapid diagnostic methods, including resistance testing. This may provide further data for surveillance systems, reporting both antibiotic consumption and resistance levels. The involvement of clinical doctors in teaching and research in this area is probably the most important aspect, along with their involvement in the formulation of national and local guidelines. In the future we may consider it more important to ensure that future patients can be offered antibiotic treatment, rather than focusing on the patient presenting today.

Entities:  

Mesh:

Year:  1998        PMID: 9990406     DOI: 10.1046/j.1365-2133.1998.1390s3004.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  10 in total

1.  Treatment for impetigo.

Authors:  Sander Koning; Johannes C van der Wouden
Journal:  BMJ       Date:  2004-09-25

2.  The prevalence of bacterial resistance in clinical, food, water and some environmental samples in Southwest Nigeria.

Authors:  A Lateef; J K Oloke; E B Gueguimkana
Journal:  Environ Monit Assess       Date:  2005-01       Impact factor: 2.513

3.  Fusidic acid cream in the treatment of impetigo in general practice: double blind randomised placebo controlled trial.

Authors:  Sander Koning; Lisette W A van Suijlekom-Smit; Jan L Nouwen; Cees M Verduin; Roos M D Bernsen; Arnold P Oranje; Siep Thomas; Johannes C van der Wouden
Journal:  BMJ       Date:  2002-01-26

4.  Oral antibiotics in acne vulgaris: therapeutic response over 5 years.

Authors:  J Adawiyah; G Priya; B Roshidah
Journal:  Malays Fam Physician       Date:  2010-12-31

5.  The unreasonable effectiveness of my self-experimentation.

Authors:  Seth Roberts
Journal:  Med Hypotheses       Date:  2010-05-23       Impact factor: 1.538

Review 6.  Commercial Essential Oils as Potential Antimicrobials to Treat Skin Diseases.

Authors:  Ané Orchard; Sandy van Vuuren
Journal:  Evid Based Complement Alternat Med       Date:  2017-05-04       Impact factor: 2.629

Review 7.  Interventions for impetigo.

Authors:  Sander Koning; Renske van der Sande; Arianne P Verhagen; Lisette W A van Suijlekom-Smit; Andrew D Morris; Christopher C Butler; Marjolein Berger; Johannes C van der Wouden
Journal:  Cochrane Database Syst Rev       Date:  2012-01-18

8.  Acne vulgaris treatment : the current scenario.

Authors:  Sanjay K Rathi
Journal:  Indian J Dermatol       Date:  2011-01       Impact factor: 1.494

Review 9.  Mass Spectrometry-Based Bacterial Proteomics: Focus on Dermatologic Microbial Pathogens.

Authors:  Youcef Soufi; Boumediene Soufi
Journal:  Front Microbiol       Date:  2016-02-19       Impact factor: 5.640

10.  Is there an association between long-term antibiotics for acne and subsequent infection sequelae and antimicrobial resistance? A systematic review.

Authors:  Ketaki Bhate; Liang-Yu Lin; John S Barbieri; Clémence Leyrat; Susan Hopkins; Richard Stabler; Laura Shallcross; Liam Smeeth; Nick Francis; Rohini Mathur; Sinéad M Langan; Sarah-Jo Sinnott
Journal:  BJGP Open       Date:  2021-06-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.